Objectives: To investigate the words and descriptions used by haematology healthcare professionals (HCPs) to describe monoclonal gammopathy of undetermined significance (MGUS) to their patients.
| INTRODUCTION
The most prevalent of the plasma cell disorders, monoclonal gammopathy of undetermined significance (MGUS), has been shown in two independent studies to consistently precede multiple myeloma (MM), an incurable malignancy. 1, 2 Clinically, MGUS is defined using the International Myeloma Working Group definition as <30 g/L of serum monoclonal (M) protein in the absence of MM, <10% plasma cell infiltration in the bone marrow and absence of end organ damage (CRAB criteria-hypercalcaemia, renal insufficiency, anaemia and bone lesions). 3 The annual risk of progression to MM and associated malignancies is 0.5%-1%, with risk remaining elevated beyond 25 years of observation. [4] [5] [6] Given the risk of malignant transformation and increased association with medical disorders such as osteoporosis/osteopenia, fractures (particularly vertebral compression fractures), peripheral neuropathy and deep vein thrombosis, [7] [8] [9] [10] it is recommended that MGUS patients are monitored indefinitely.
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MGUS is asymptomatic, and for the majority of patients, diagnosis will be incidental following routine blood work or diagnostic workup.
From ongoing research, the study team are aware that the words and descriptions used by patients to describe their MGUS diagnosis vary.
This is in line with reports for other premalignant conditions, such as ductal carcinoma in situ, where patients report diverse terminology used by healthcare professionals including "breast cancer," "early cancer," "in situ," "premalignant," "ductal carcinoma in situ," "DCIS,"
"abnormal cells," "non-invasive" and "precancer(ous)". [12] [13] [14] For patients diagnosed with premalignant conditions, uncertainty about the condition and potential progression to cancer can resonate. 12, 15, 16 For this reason, healthcare professionals may choose simpler terminology to describe the condition at the point of diagnosis and follow-up care. How premalignant diagnoses are communicated to patients is of paramount importance to reduce the psychosocial impact of diagnosis. 12, 16, 17 Patients with haematological malignancies report varied needs for information on the disease, treatment and prognosis with tailored communication to the patient advocated. 18 Likewise, provision of accurate and timely information for MGUS patients is equally important. To date, we are unaware of any published literature describing how a diagnosis of MGUS is communicated to patients, the terminology used or the provision of communication aids. 19 We report here on the words and descriptions used by haematology healthcare professionals to describe MGUS to their patients and their views towards follow-up.
| METHODS
A cross-sectional survey of healthcare professionals attending the an- 
| Survey
The study team developed a short survey consisting of nine questions. The remaining questions explored the words and descriptions used by healthcare professionals on the island of Ireland to describe MGUS to their patients. Questions about the use of information leaflets and follow-up recommendations were also included. Each survey was labelled with a unique number, and all survey responses were anonymous.
All attendees were provided with the survey together with the study poster and information booklet within their meeting programme. Only healthcare professionals (doctors, nurses and allied healthcare professionals) were instructed to complete the survey. To increase awareness of the study, the study poster was displayed on the presentation screen at the end of the oral presentation sessions and posters were also displayed throughout the main meeting rooms.
Participants were asked to return the completed surveys to the boxes labelled "MGUS study" which where located in strategic locations throughout the meeting venue. Respondents were entered into a draw for an iPad mini™.
| Data analysis
The returned survey responses were entered into Microsoft Excel. 
| RESULTS
In total, 55 people responded to the survey (Table 1) 
| Describing MGUS to patients
When asked in an open-ended question, "How do you describe MGUS to your patients?", the majority (60%) of respondents favoured simple
Key Findings & Recommendations
• Haematology healthcare professionals often use simplistic terminology to describe MGUS to their patients.
• Healthcare professionals require easy access to patientfriendly information leaflets.
• Increased support for GPs in diagnosing and following up MGUS patients may be required and could be supported through the development of guidelines which provide clear instructions on how to manage MGUS patients.
T A B L E 1 Summary of survey responses
All respondents (n = 55)
Republic of Ireland respondents (n = 41)
Northern Ireland respondents (n = 13) P-value language such as the presence of an "abnormal protein in the blood" requiring ongoing monitoring (Table 2 ). Only 38.2% (n = 21) of respondents included the terms premalignant, precancer or cancer (eg MM, blood/bone marrow cancer or haematological malignancy)
within their responses to this question. To aid understanding, some reported using analogies that the patient was more likely to be familiar with such as "like a mole we need to watch" and "finding a paraprotein is a bit like finding a 'lump' and needing to investigate further whether benign or malignant." Signs/symptoms and/or the need to monitor bloods, kidneys and bones for future problems were specifically mentioned by 18.2% (n = 10) respondents. Only 7.3% (n = 4) of respondents, all of whom were doctors (n = 3 consultants and n = 1 registrar), reported telling patients of the relationship between MGUS prevalence and advancing age. Overall, respondents were keen to reassure I tell some patients it is not a disease but a "predisease" state. (Consultant)
A protein that you don't need and in some people can progress into a disease that causes harm but is treatable.
I sometimes explain to patients that finding a paraprotein is a bit like finding a "lump" and needing to investigate further whether benign or malignant-generally patients find this concept easier to understand. (Consultant)
An abnormal protein that in most people needs just watching but can start to cause damage and develop into a blood cancer "like a mole we need to watch". (Registrar)
A sleeping condition that may or may not ever cause any problems/progress to myeloma. (Nurse) Do you tell patients that they have "MGUS" or "monoclonal gammopathy of undetermined/uncertain significance?"
I believe most patients want to know and take some ownership. Also, it allows patients to educate themselves. their patients that MGUS was unlikely to cause any harm, but ongoing follow-up/monitoring is needed in case of changes/symptoms requiring treatment.
| Telling patients they have MGUS
Excluding those (n = 7) who stated that informing patients of their diagnosis was not applicable to their job role (specialist nurse/nurse/ allied healthcare professional), the majority of respondents (79.2%; n = 38 of 48) reported telling "all patients" that they had MGUS using either the term "MGUS" or "monoclonal gammopathy of undetermined/uncertain significance". An additional 20.8% (n = 10) stated that they only told "some patients". While telling patients provided an opportunity for ownership and education, others stated educational level, age and cognitive ability were important factors in deciding how to relay the information ( Table 2 ). Often in these situations, respondents chose to use simpler terms such as "abnormal protein" to convey the message.
| Telling patients of their risk of progression
In terms of informing patients of their risk of progression to a haematological malignancy, 69.1% (n = 38 of 55) reported telling "all patients" while 16.4% (n = 9) reported telling only "some patients."
Respondents who stated "No" or wrote "unsure" in response to this question (n = 8) came from nursing/allied healthcare professional backgrounds (n = 2 specialist nurses, n = 5 nurses and n = 1 allied healthcare professional). One specialist nurse confirmed in free text that they did not tell their patients the risk of myeloma, while the majority felt that communication of risk was the doctor's duty. Those who reported telling "all patients" were keen to highlight the low risk of progression and referred to published estimates on MGUS progression/risk stratification from the Mayo Clinic studies (Table 2) . Others felt that patients needed to be aware of the risk as a rationale for the ongoing monitoring either by their haematology team or GP. The importance of informing patients on risk of progression to myeloma was highlighted by one respondent who said it would be better to do so in case the patient looked MGUS up on the Internet (Table 2 ).
Another respondent stated that they avoid using the terms progression to "cancer" or "malignancy" and instead describe progression to a "blood condition" unless the patient enquires further, in which case progression to "a type of blood cancer" is discussed. Being elderly/frail were cited as reasons to avoid telling patients of their risk of progression as it was stated that this could cause anxiety or distress to the patient. One respondent stated that risk of progression would only be disclosed to such patients if an increase in paraprotein was detected in follow-up. One consultant stated that they told their patients of the risk of progression "less than I probably should".
| Information leaflet
Overall, 41.8% (n = 23 of 55) of respondents reported providing all patients with a MGUS information leaflet. An additional 27.3% (n = 15)
reported providing an information leaflet if asked by the patient, while 23.6% (n = 13) did not give out information leaflets. The majority of nurses (61.9%) reported providing information leaflets to all of their patients compared to 31.3% of doctors, while healthcare professionals in Northern Ireland appeared more likely than those in the Republic of Ireland to give an information leaflet to all patients (53.8% vs 39%). Although no free text option was provided for this question, some respondents provided additional comments stating that some patients declined information leaflets, while others highlighted the lack of appropriate information leaflets and difficulties accessing these resources.
| Follow-up
Excluding the three individuals from nursing backgrounds who earlier in the survey stated that the decision-making process was not part of their job role, more than half of the respondents (53.8%, n = 28 of 52) reported that all MGUS patients should be reviewed frequently;
32.7% (n = 17) reported that follow-up should be aimed at patients considered to be at intermediate/high risk of progressing while 25%
(n = 13) reported that follow-up should involve primary care. Of the 52 respondents, 78.8% (n = 41) provided additional information to this question. Many agreed that a combined approach to follow-up was favourable with low-risk MGUS patients being followed up by their GP (if willing) and the intermediate/high-risk patients being reviewed frequently by their haematology healthcare team ( Table 2 ).
The frequency of follow-up suggested by respondents varied with some suggesting that it should be based on risk of progression while others reported following up patients at varying intervals such as 3-4 months, 6 months or annually. Some felt that follow-up could be nurse-led and via telephone clinics as "clinic appointments create unnecessary stress to otherwise well patients". Those advocating for follow-up in primary care suggested that GPs should be supported in this process through the provision of clear instructions on follow-up procedures and the signs and symptoms to look out for.
| Awareness of MGUS
Of the 55 respondents, 29.1% (n = 16) provided additional comments they believed would be of interest to the study team. The predominant focus of these comments concerned the lack of awareness and understanding of MGUS by healthcare professionals outside haematology which was described as being "generally poor." Particular ref-
erence was made to GPs who were highlighted as needing support to avoid over-diagnosing and over-referring patients to haematology with abnormal serum protein electrophoresis results. Recognising detection of a paraprotein can "cause unnecessary anxiety," it was suggested that guidelines are needed to assist healthcare professionals in deciding the appropriate time to test for paraproteins. Similarly, it was highlighted that MGUS patients are often not well-informed and can find it difficult to comprehend MGUS, "often as much as I try to explain they still don't understand." As with other patients on watch and wait surveillance, one respondent stated that MGUS patients represent "a hugely neglected cohort of patients from a nursing input"
and that patients could benefit from access to a patient-friendly information leaflet.
| DISCUSSION
The findings of this study suggest that while the majority of MGUS patients are informed of their diagnosis, there may be situations where haematology healthcare professionals decide that alternative terminology is necessary. Age, education and cognitive ability were cited as the main reasons for withholding information about the condition and/or the risk of progression to myeloma and associated malignancies. The findings of this study have implications for patients and healthcare professionals alike.
The main strength of our study was that we were able to capture the views of a range of healthcare professionals within haematology from two different healthcare systems. As a region of the United Kingdom, Northern Ireland uses the National Healthcare System (NHS) which provides free health care for all. In contrast, In conclusion, this survey of haematology healthcare professionals has highlighted a number of important issues for patients and healthcare professionals. Moving forward, it is imperative that guidelines are developed to assist healthcare professionals outside haematology, particularly GPs, in managing MGUS patients.
